Pobirci D D, Bogdan Fl, Pobirci Oana, Petcu Carmen Adina, Roşca Elena
Orthopedic Section I, County Hospital, University of Oradea, Romania.
Rom J Morphol Embryol. 2011;52(1 Suppl):385-8.
Malignant fibrous histiocytoma (MFH) is a malignant tumor of soft parts observed at approximately 70% of cases situated at the level of the outsides.
Our study is formed of 14 cases of patients in a period of three years (2007-2010), diagnosed anatomo-pathological with malignant fibrous histiocytoma at the County Hospital of Oradea. The histopathological examination together with the immunohistochemical one is of vital importance in the establishment of the positive diagnostic and furthermore in the establishment of the differential diagnostic with carcinomas, plasmacytomas, osteosarcomas, fibrosarcomas and lymphosarcomas, fact that arouse the doctors to administrate the correct treatment to a specific patient.
MFH is a tumor of late adulthood that occurs in men more commonly than women. Computer tomography and MRI have been widely used in the diagnosis and staging of MFH. MFH is secondary to another process such as radiation, surgery, fracture, osteonecrosis, Paget's disease, non-ossifying fibroma or fibrous dysplasia 20% of the time. MFH arising from a previous abnormality is usually more aggressive and has a poorer prognosis than primary MFH. Primary osseous MFH is a central lesion found in the diaphysis or metaphysis of the bone that causes aggressive bone destruction and a soft tissue mass. The most common sites in order are the distal femur, proximal tibia, proximal femur and proximal humerus. Primary osseous MFH is less common. MFH is found in the extremities 70-75% of the time and 50% of all cases are in the lower extremity. Other less common sites include the retroperitoneum, and the head and neck. In our study, of 14 patients with malignant fibrous histiocytoma, the highest incidence is during the sixth decade of life and there is a male to female ratio of 8 to 6. In the specialty literature, malignant fibrous histiocytoma tend to occur in children and teenagers but can also occur in older adults as secondary lesions in bone infarcts and radiation fields. This tumor is clinically similar to osteosarcoma and fibrosarcoma, although malignant fibrous histiocytomas have been classified as different from the osteosarcoma group because of a different histology (no tumor bone production). Treatment is similar to that of osteosarcoma.
During our study, the average age was of 61 years in comparison with the specialty literature where the average age was of 50 years. The same as in the specialty literature the cases of fibrous malignant histiocytoma studied are more frequently present at men. Regarding the situation, our study shows the affectation of the long bones especially the femur followed by the radius. The histopathological examination together with the immunohistochemical one is of vital importance in the establishment of the positive diagnostic and furthermore in the establishment of the differential diagnostic with carcinomas, plasmacytomas and lymphosarcomas.
恶性纤维组织细胞瘤(MFH)是一种软组织恶性肿瘤,约70%的病例发生于体表部位。
我们的研究涵盖了3年(2007 - 2010年)期间在奥拉迪亚县医院经解剖病理学诊断为恶性纤维组织细胞瘤的14例患者。组织病理学检查以及免疫组织化学检查对于确诊至关重要,而且对于与癌、浆细胞瘤、骨肉瘤、纤维肉瘤和淋巴瘤进行鉴别诊断也很关键,这促使医生为特定患者实施正确的治疗。
MFH是一种好发于成年人后期的肿瘤,男性发病多于女性。计算机断层扫描(CT)和磁共振成像(MRI)已广泛应用于MFH的诊断和分期。20%的MFH继发于其他病变,如放疗、手术、骨折、骨坏死、佩吉特病、非骨化性纤维瘤或骨纤维异常增殖症。由先前异常引发的MFH通常比原发性MFH更具侵袭性,预后更差。原发性骨MFH是一种位于骨干或干骺端的中心性病变,可导致侵袭性骨质破坏和软组织肿块。按常见程度依次为股骨远端、胫骨近端、股骨近端和肱骨近端。原发性骨MFH相对少见。70 - 75%的MFH发生于四肢,所有病例中有50%位于下肢。其他较少见的部位包括腹膜后以及头颈部。在我们的研究中,14例恶性纤维组织细胞瘤患者中,最高发病率出现在60岁左右,男女比例为8比6。在专业文献中,恶性纤维组织细胞瘤倾向于发生在儿童和青少年,但也可作为骨梗死和放疗区域的继发性病变发生于老年人。这种肿瘤在临床上与骨肉瘤和纤维肉瘤相似,尽管由于组织学不同(无肿瘤骨形成),恶性纤维组织细胞瘤已被归类为与骨肉瘤不同的类型。治疗方法与骨肉瘤相似。
在我们的研究中,平均年龄为61岁,而专业文献中的平均年龄为50岁。与专业文献相同,所研究的纤维性恶性组织细胞瘤病例在男性中更为常见。就情况而言,我们的研究表明长骨尤其是股骨受累,其次是桡骨。组织病理学检查以及免疫组织化学检查对于确诊至关重要,而且对于与癌、浆细胞瘤和淋巴瘤进行鉴别诊断也很关键。